U.S. Appeals Court Upholds $25 Million Roundup Verdict Against Bayer

A federal appeals court upheld a $25 million judgment and trial verdict finding Roundup caused a California resident’s non-Hodgkin lymphoma, dealing a blow to Bayer’s hopes of limiting legal risk over the weed killer.

All CPDA Certified Adjuvants are eligible for the certification. Applications must be received by January 15, 2023 to be included in the first round of testing.
All CPDA Certified Adjuvants are eligible for the certification. Applications must be received by January 15, 2023 to be included in the first round of testing.
(Margy Eckelkamp)

A federal appeals court on Friday upheld a $25 million judgment and trial verdict finding Bayer’s Roundup caused a California resident’s non-Hodgkin lymphoma, dealing a blow to the chemical company’s hopes of limiting its legal risk over the weed-killer. The trial judge did not misapply the law when he allowed the lawsuit by Edwin Hardeman to go to trial, as Bayer has argued, according to a three-judge panel of the 9th U.S. Circuit Court of Appeals in San Francisco.

A jury in 2019 awarded Hardeman $5 million in compensatory damages and $75 million in punitive damages. The punitive award was later cut to $20 million, and the appeals court also upheld the reduction.

The Hardeman case was the first so-called bellwether trial for federal cases alleging Roundup causes cancer. Bayer has said that decades of studies have shown Roundup and other glyphosate-based herbicides that dominate the market are safe for human use.

Bayer has committed $9.6 billion to settle 125,000 claims over Roundup and next week will seek preliminary approval for a $2 billion proposed deal to resolve future claims by consumers who have been exposed to Roundup but have not yet gotten sick.

(Reporting by Tom Hals in Wilmington, Delaware; additional reporting by Nate Raymond in Boston; Editing by Diane Craft and Dan Grebler)

AgWeb-Logo crop
Related Stories
After Calley Means alleges White House corruption on high-profile podcasts, commodity leaders urge Washington to choose peer-reviewed science over soundbites.
Industry leaders say the products must deliver consistent agronomic results and measurable economic returns to earn their place in farmers’ input lineup.
Voraxor adds a new PPO active, trifludimoxazin, to a burndown that already leans on a PPO partner; Zidua PLUS is a repositioned premix.
Read Next
First-time detections in Iowa and Alabama highlight the importance of accurate identification and proactive seed treatment strategies.

Get News Daily
Get Market Alerts
Get News & Markets App